Rare Disease Biotech Zevra Therapeutics to Sell FDA Drug Review Fast Pass for $150M
Zevra Therapeutics received a priority review voucher for Miplyffa, the first FDA-approved treatment for the rare metabolic disorder Niemann Pick disease type C. Though Zevra has other drug candidates that could benefit from the voucher, the biotech is selling it to an undisclosed buyer. The post Rare Disease Biotech Zevra Therapeutics to Sell FDA Drug Review Fast Pass for $150M appeared first on MedCity News.
Zevra Therapeutics received a priority review voucher for Miplyffa, the first FDA-approved treatment for the rare metabolic disorder Niemann Pick disease type C. Though Zevra has other drug candidates that could benefit from the voucher, the biotech is selling it to an undisclosed buyer.
The post Rare Disease Biotech Zevra Therapeutics to Sell FDA Drug Review Fast Pass for $150M appeared first on MedCity News.
